DEO reports its fiscal 2026 half-year results on May 8 fresh from a bruising February print. Options traders have flipped decisively bullish ahead of the release — the put/call ratio has collapsed from above 0.90 to 0.65, nearly a full standard deviation below its 20-day average. That's close to the lowest defensive reading of the past year (52-week low: 0.59), suggesting investors are no longer hedging the way they were when the stock was 30% higher.
That shift in options sentiment is the most striking feature of the current setup. The PCR stood above 0.90 for much of March and early April — cautious positioning consistent with a stock nursing a severe wound. The February 25 earnings release triggered a 16% single-day collapse and a 19% five-day loss, one of the sharpest single-event moves in the spirits sector in recent memory. Yet the PCR has compressed hard over the past three weeks, pointing to a view that the worst is already priced at $78.51. The stock has recovered 7% over the past month even as it slipped 1.5% on Monday.
Short interest tells a less comfortable story. Estimated short positions rose roughly 25% in the two-week window following April 22, lifting the share count to around 4.3 million — a meaningful build that follows a period of relative calm. Days to cover stands near 1.7, so there's no imminent squeeze threat, and borrow remains cheap at 0.80% APR. But availability has tightened noticeably: the borrow pool hit its 52-week tightest point on April 24 before easing back to around 86% utilisation. New shorts face less friction than at the February event, but the build itself is a sign of lingering scepticism.
The fundamental debate centres on whether the February profit warning was a reset or the start of a longer downturn. Diageo's EV/EBITDA at approximately 11x sits near multi-year lows for a franchise that once commanded a premium for its resilient cash flows — operating cash generation runs near $4.2 billion annually. The dividend score ranks in the 91st percentile of the ORTEX universe, underlining the income credentials that underpin long-term holders like BlackRock (7.4% stake) and Vanguard (5.5%). Against that, bearish voices point to the $20 billion net debt load and a spirits market still digesting post-pandemic de-stocking. Recent analyst activity (the most current data available being from December 2025) showed UBS downgrading to Neutral, while BofA maintained Buy after cutting its target from $117 to $109 — reflecting a Street that hasn't abandoned the thesis but has meaningfully lowered the bar. Caution is warranted on any target price data predating 2026 given how sharply the ADR has re-rated.
The May 8 release will test whether management can demonstrate that volume trends are stabilising across Latin America and the US spirits channel, and whether the cost-cutting programme announced in February is delivering enough margin support to justify any re-rating from the stock's depressed multiple.
See the live data behind this article on ORTEX.
Open DEO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
